Suchergebnisse - "Okuma, Yusuke"

PubPharm (289)

1

Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis : a propensity-matched real-world analysis

enthalten in: Journal of cancer research and clinical oncology | 2024

von Tamura, K. | Okuma, Y. | Nomura, S. | +9

2

Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis

enthalten in: Journal of cancer research and clinical oncology | 2024

von Tamura, K. | Okuma, Y. | Nomura, S. | +9

3

Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Miyakoshi, J. | Yoshida, T. | Kashima, J. | +14

4

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma : Results from the multicenter, phase 2 REMORA trial

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Niho, S. | Sato, J. | Satouchi, M. | +12

5

Patient survey on cancer genomic medicine in Japan under the national health insurance system

enthalten in: Cancer science | 2024

von Kage, H. | Akiyama, N. | Chang, H. | +20

6

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations

enthalten in: JTO clinical and research reports | 2024

von Takeyasu, Y. | Yoshida, T. | Masuda, K. | +7

7

Artemis : A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas

enthalten in: Clinical lung cancer | 2024

von Okuma, Y. | Nomura, S. | Sakakibara-Konishi, J. | +9

8

Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations : Findings from the Japanese Lung Cancer Registry Database

enthalten in: Clinical lung cancer | 2024

von Okuma, Y. | Shintani, Y. | Sekine, I. | +10

9

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations : The UNICORN Phase 2 Nonrandomized Clinical Trial

enthalten in: JAMA oncology | 2024

von Okuma, Y. | Kubota, K. | Shimokawa, M. | +9

CommentOn: JAMA Oncol. 2024 Jan 1;10(1):52-53. - PMID 37991771

10

A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence

enthalten in: JAMA oncology | 2024

von Sunami, K. | Naito, Y. | Saigusa, Y. | +32

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[29]